A 2024 meta-analysis focusing on PCOS patients revealed that GLP-1 receptor agonists significantly lowered fasting insulin levels, improved results on the 2-hour postoral glucose tolerance test, and reduced HOMA-IR, a key marker of insulin resistance
In addition, a critical appraisal of emerging therapeutic modalities targeting mitochondrial function is provided, including mitochondria-targeted antioxidants, bioenergetic modulators, and agents that enhance mitochondrial quality control mechanisms
Clinical trial data supports this, showing non-responder rates around 13% for Semaglutide (Wegovy/Ozempic) and 9% for Tirzepatide (Zepbound/Mounjaro)
Jain S, Singh R, Paliwal T et al (2025) Discovery of novel fatty acid amide hydrolase (FAAH) inhibitors as anti-alzheimer agents via in-silico-based drug design, virtual screening, molecular docking, molecular dynamics simulation, DFT, and non-clinical studies
Transient 5-oxoprolinuria: unusually high anion gap acidosis in an infant
Clinical Safety & Considerations Before starting peptide therapy: Get Baseline Labs: IGF-1 Fasting glucose and insulin Lipid panel Thyroid and cortisol markers Monitor: Response to treatment Sleep quality and muscle recovery Adverse effects: water retention, joint pain, injection site irritation Contraindications: Active cancer Uncontrolled diabetes Pregnant or breastfeeding Prior history of pituitary disorders All peptides should be prescribed and monitored by a licensed medical provider using pharmaceutical-grade compounds
